Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Canopy Growth (NASDAQ: CGC) and Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup with new 30- and 90-pack formats and added dosing options across the Optimized Spectrum portfolio. Clarity, Unwind, and Daily Relief 90-packs are available now; two SKUs (30-pack Daily Relief higher-dose, 90-pack Nighttime Relief) roll out at the end of May.
The portfolio adds daytime and nighttime formulations, a higher-dose 30-pack, and aims to improve dosing flexibility, patient adherence, affordability, and clinical alignment.
Canopy Growth (NASDAQ: CGC) unveiled a national summer refresh for its Tweed brand titled “There’s a Tweed for That.” The campaign launches over the Victoria Day long weekend and highlights updated packaging, three new flower strains, Quickies pre-rolls, improved potency, sharper pricing, and a new milled format coming summer 2026.
The refresh adds window bags so consumers can see flower SKUs, and the lineup includes whole and milled flower, pre-rolls, Liquid Diamond vapes and softgels.
Canopy Growth (CGC) launched a new value-focused cannabis brand, Deelish, on March 31, 2026, offering high-potency flower and pre-rolls at everyday price points.
Deelish debuts four SKUs: two 28g whole-flower SKUs and two 2x1g pre-roll SKUs, with flower testing 27%-33% THC and pre-rolls 26%-32% THC. The brand features rotating genetics and is now available at select stores in Ontario and Alberta.
Canopy Growth (NASDAQ: CGC, TSX: WEED) said its Apollo Cannabis Clinics was named Best Medical Cannabis Clinic in the 2025 Toronto Star Readers’ Choice Awards on March 30, 2026. The award reflects public voting and patient trust in Apollo’s care.
Apollo offers Canada-wide, free fully virtual medical cannabis consultations with no referral required, personalized treatment plans, and ongoing support. According to the company, Apollo has helped thousands of Canadians manage chronic pain, anxiety, sleep disorders, PTSD, and other conditions.
Canopy Growth (Nasdaq: CGC) announced that David Männer will become Managing Director of Storz & Bickel effective April 1, 2026, succeeding co-founder Jürgen Bickel, who is transitioning after 25 years of leadership. Männer is a 14-year company veteran and most recently served as Deputy Managing Director.
Canopy said the move preserves operational continuity, supports plans to deepen presence in the U.S., and intends to continue product innovation under new leadership.
Canopy Growth (Nasdaq: CGC; TSX: WEED) completed its acquisition of MTL Cannabis on March 16, 2026, creating Canada’s leading medical cannabis business by revenue. The deal: MTL became a wholly owned subsidiary, MTL shares to be de-listed, and consideration included 0.32 Canopy shares plus $0.144 cash per MTL share.
The transaction issued ~41.2 million Canopy shares and paid ~$18.5 million cash. Expected run-rate synergies are ~$10 million within 18 months and the combined business supports a path to positive adjusted EBITDA in fiscal 2027.
Canopy Growth (Nasdaq: CGC) said MTL Cannabis shareholders overwhelmingly approved Canopy’s acquisition plan at a Feb 17, 2026 special meeting.
The vote saw 99.97% approval of all MTL shares and ~89% turnout. Closing remains subject to customary conditions and is expected before the end of March 2026.
Canopy Growth (Nasdaq: CGC) reported Q3 FY2026 results for the three months ended December 31, 2025, showing improving fundamentals in Canada and narrowing losses.
Key highlights: consolidated net revenue of $75M, cannabis net revenue of $52M, adjusted EBITDA loss narrowed to $3M, net loss narrowed 49% YoY, cash and equivalents $371M, net cash position $146M. Acquisition of MTL Cannabis on track to close in the current quarter.
Canopy Growth (NASDAQ:CGC) will release third quarter fiscal 2026 financial results for the period ended December 31, 2025 before markets open on February 6, 2026. The company will host a live audio webcast with CEO Luc Mongeau and CFO Tom Stewart on February 6, 2026 at 10:00 AM ET to discuss results.
A live audio webcast will be available at the provided link, and a replay will remain accessible by webcast until 11:59 PM ET on May 7, 2026.
Canopy Growth (Nasdaq: CGC, TSX: WEED) announced a series of recapitalization transactions closing on or around January 8, 2026 that extend all outstanding debt maturities to at least January 2031 and are expected to leave the company with approximately C$425 million in cash. Key elements include a Term Loan providing net proceeds of US$150 million (aggregate principal ~US$162M) maturing Jan 2031 and an exchange of ~C$96.4M of debentures for C$55M of new convertible debentures due July 2031, C$10.5M cash, 9,493,670 common shares and 12,731,481 warrants. Transaction warrants and registration rights will be issued; customary fees, covenants and security on substantially all assets apply.